Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

leo pharma a/s beiname: leo pharmaceutical products ltd. a/s (3180623) - natriumfusidat - filmtablette - natriumfusidat (7378) 0,25 gramm

Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunsuppressiva - simulect ist indiziert zur prophylaxe bei akuter abstoßungsreaktionen in de-novo allogene nierentransplantation bei erwachsenen und pädiatrischen patienten (1-17 jahre). es ist zu sein verwendet in verbindung mit für ciclosporin mikroemulsion und kortikosteroiden basierenden immunsuppression bei patienten mit panel-reaktive antikörper, die weniger als 80%, oder in einem dreifach-wartung immunsuppressive therapie mit ciclosporin mikroemulsion für, kortikosteroiden und entweder azathioprin oder mycophenolatmofetil.

Europäische Union - Deutsch - EMA (European Medicines Agency)

astellas pharma europe b.v. - tacrolimus - transplantatabstoßung - immunsuppressiva - prophylaxe der transplantatabstoßung bei erwachsenen und pädiatrischen, niere, leber oder herz allograft-empfängern. behandlung von abstoßungsreaktionen resistent gegen die behandlung mit anderen immunsuppressiven arzneimitteln bei erwachsenen und pädiatrischen patienten.

Europäische Union - Deutsch - EMA (European Medicines Agency)

roche registration ltd. - daclizumab - graft rejection; kidney transplantation - immunsuppressiva - zenapax ist indiziert für die prophylaxe von akuten abstoßungsreaktionen in de novo allogene nierentransplantation und soll damit auch verwendet werden, mit einer immunsuppressiven therapie, einschließlich ciclosporin und corticosteroiden bei patienten, die nicht hoch geimpft sind.

Europäische Union - Deutsch - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantatabstoßung - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europäische Union - Deutsch - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunsuppressiva - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Europäische Union - Deutsch - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - duloxetinum - kapseln gastrorésistantes - duloxetinum 30 mg zu duloxetini hydrochloridum, zucker, hypromellosi acetas succinas, hypromellosum, zucker-kugeln, talk, triethylis citras, e 171, matériel de la capsule: e 132, e 171, gelatine, natrii laurilsulfas, encre: lacca, propylenglycolum, kalii hydroxidum, e 172 (schwarz), e 172 (gelb), für die kapsel endwerte. zucker 56 mg, natrium 0.0055 mg. - antidepressiva, diabetischen neuropathischen schmerz, störung der generalisierten angst - - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - duloxetinum - kapseln gastrorésistantes - duloxetinum 60 mg zu duloxetini hydrochloridum, zucker, hypromellosi acetas succinas, hypromellosum, zucker-kugeln, talk, triethylis citras, e 171, matériel de la capsule: e 132, e 171, gelatine, natrii laurilsulfas, e 172 (gelb), encre: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, für eine kleine box endwerte. zucker 111 mg, natrium 0.0086 mg. - antidepressiva, diabetischen neuropathischen schmerz, störung der generalisierten angst - - synthetika

Schweiz - Deutsch - OFAG-BLW (Bundesamt für Landwirtschaft)

sivam s.p.a. - mancozeb - 11304 - italien - fungizid ;